Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

London, United Kingdom (PressExposure) July 28, 2011 -- The global Drug Eluting Stents (DES) market was valued at about $4.6 billion in 2010. The market was estimated at $1.69 billion in 2003 and has registered a Compound Annual Growth Rate (CAGR) of 15.4% since. The market is expected to remain stagnant in the future on account of decreasing average selling prices (ASP). However the volumes are expected to increase due to the higher adoption of DES in the treatment of Coronary Heart Disease (CHD).

In 2010, the prevalence of CHD in the US was 8%. According to the National Health and Nutrition Examination Survey (NHANES) 2005-2008 data, about 16.3 million adults (>=20) were suffering from CHD in the US. About 800,000 people will suffer from a new coronary attack annually, while 500,000 will suffer a recurring one. At the current rate, the prevalence of the disease will rise to 9.3% by 2030 and lead to an increase of about eight million patients suffering with CHD.

In the UK, the prevalence of CHD was 3.8% in 2008. An estimated 2.7 million people were suffering from CHD in 2010. The rate was higher in men compared to women. The British Heart Foundation (BHF) estimates that about 88,000 deaths occurred due to CHD in 2008.

The US was estimated as the largest DES market with a value of about $2 billion in 2010. The DES market in the US increased from $1.1 billion in 2003 to $2 billion in 2010 at a CAGR of 8.6%. The increase in revenues was due to the wide acceptance of DES by physicians in the US. However, due to unfavorable scientific studies in 2006-2007, the revenues declined drastically.

The number of drug eluting stents implanted in Percutaneous Coronary Intervention (PCI) procedures increased from 440,000 in 2003 to 1.16 million in 2010. The largest volume was recorded in 2005 at 1.32 million. The penetration of DES in PCI stenting has increased from 32% in 2003 to 68% in 2010. The highest penetration was recorded in 2005 at 87%.

For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Drug-Eluting-Stents-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017&Title=Medical_Devices&ReportType=Industry_Report&CompanyID=pexpo

Increase in the incidence of cardiovascular disease (CVD) is expected to lead to higher demand for DES. The increase in incidence of CVD is due to a variety of factors, such as obesity, diabetes, smoking, alcohol consumption, unhealthy lifestyles, and aging populations, among others. Obesity is one of the leading causes of cardiovascular diseases. The World Health Organization (WHO) estimates that about 105 million people globally are overweight. Severely obese people have a reduced life span of 8-10 years. Obesity leads to about 2.8 million deaths every year. Obesity is known to be the underlying cause in about 23% of ischemic heart disease cases.

According to the WHO, globally about 285 million people are affected with diabetes in 2010. By 2030, about 8% of the global population, comprising about 438 million people, is expected to suffer from diabetes. In 2004, about 2.3 million deaths were caused by diabetes. The number of deaths is expected to double by 2030. For people with the underlying condition of diabetes, the probability of developing CVD increases by two to four times. About 25 million people are affected by diabetes in the US. In the UK, about 2.8 million people suffer from diabetes. India and China have the largest numbers of patients suffering from diabetes. According to the World Diabetes Foundation, India had an estimated 50.8 million and China 43.2 million people suffering from diabetes in 2010. Currently the largest numbers of diabetic individuals occur in the 40-59 age-group. By 2030, this age-group will shift to the >60 age-group, adding another 198 million people suffering from diabetes.

GlobalData's new report, "Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" provides key data, information and analysis on the global drug eluting stents market. The report provides market landscape, competitive landscape and market trends information on the drug eluting stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Drug-Eluting-Stents-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medical_Devices&CompanyID=pexpo

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:


North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782

About GlobalData

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: July 28, 2011 at 1:38 am
This article has been viewed 89914 time(s).